Neutropenia Occurs More Often Under Carbimazole than Under Methimazole Treatment in Pediatric Graves’ Disease Patients
- 24 June 2024
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 34 (6) , 735-743
Abstract
Background: Agranulocytosis is a rare antithyroid drug treatment (ATD) side effect seen in children suffering from Graves’ disease (GD). Neutropenia is a recognized adverse event associated with ATD but has also been reported as pre-treatment neutropenia in GD. Methods: We performed a retrospective cohort study to analyze the longitudinal clinical and biochemical data of 161 pediatric patients with GD who received either methimazole (MMI) or carbimazole (CBZ) as ATD. The inclusion criteria were elevated free thyroxine (fT4 >25 pmol/L), suppressed thyrotropin (TSH 2.5 IU/L). Absolute neutrophil count (ANC) was used to define neutropenia (ANC p = 0.07) and those without neutropenia before and during therapy (23.12 pmol/L ± 13.7; p = 0.003). Thirty-eight patients (23.6%) became neutropenic (ANC: 1479/µL ± 262) while receiving ATD. Neutropenia occurred after a mean of 551.8 (range: 10–1376) days, mostly without further deterioration. Two of these 38 patients developed agranulocytosis and underwent emergency thyroidectomy. The patients with neutropenia were significantly younger ( p = 0.031). Neutropenia occurred significantly more often in patients receiving CBZ (50%; n = 20/40) than in those receiving MMI (16.5%; n = 18/110; p = 0.001). The minimum ANC was significantly lower in the CBZ (1971/µL ± 1008) than in the MMI group (2546 ± 959); p = 0.004. Conclusions: Neutropenia occurred significantly more often under CBZ than MMI. As this is potentially due to higher immunogenicity, we suggest that children with GD should be treated with MMI. Frequent measurements of ANC may be needed to detect severe agranulocytosis, although low pre-treatment ANC may not necessarily be a contraindication to ATD treatment. Young age may be potentially associated with an increased risk of reduced ANC. Further investigation is necessary to fully understand risk factors for neutropenia in children with GD.Keywords
This publication has 23 references indexed in Scilit:
- Non–chemotherapy drug–induced neutropenia: key points to manage the challengesHematology-American Society Hematology Education Program, 2017
- Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and ManagementDrugs in R&D, 2017
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of ThyrotoxicosisThyroid®, 2016
- Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves’ diseaseInternational Journal of Pediatric Endocrinology, 2016
- Treatment of hyperthyroidism with antithyroid drugs corrects mild neutropenia in Graves' diseaseClinical Endocrinology, 2016
- Methimazole-Induced Agranulocytosis in Patients with Graves' Disease Is More Frequent with an Initial Dose of 30 mg Daily than with 15 mg DailyThyroid®, 2009
- Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UKClinical Endocrinology, 2004
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenNew England Journal of Medicine, 2003
- Neutropenia and anaemia due to carbimazole-dependent antibodiesBritish Journal of Haematology, 2000
- Antineutrophil autoantibodies in Graves' disease. Implications of thyrotropin binding to neutrophils.Journal of Clinical Investigation, 1985